幹細胞による人工血液の研究:RhoBの転写抑制因子としてBRD4が末端赤血球生成を阻害する新たな役割とメカニズムを解明。(Stem cell-derived red blood cell production advances for artificial blood supply)

ad

2025-09-08 浙江大学(ZJU)

浙江大学医学部附属第一医院の黄鶴教授らは、転写因子BRD4が赤血球の終末分化を抑制する新しい仕組みを解明しました。通常は転写活性化因子として知られるBRD4が、小型GTP結合タンパク質RhoBの発現を抑制し、アクチン再編成を阻害することで赤芽球の成熟と脱核を妨げていることを発見。BRD4阻害剤を用いた実験では、CD34+造血幹細胞や多能性幹細胞から分化した前駆細胞で赤血球成熟と脱核効率が有意に向上しました。マルチオミクス解析により、この作用が従来の相互作用パートナーCDK9とは独立していることも判明。さらに、BRD4がヒストンメチル基転移酵素EHMT1/2と相互作用して転写抑制機能を発揮することを実証しました。本成果はJournal of Hematology & Oncologyに掲載され、人工血液開発の効率化や骨髄異形成症候群など造血障害治療の新しい標的となる可能性を示しています。

<関連情報>

BRD4はRhoBの転写抑制因子として作用し、末梢赤血球生成を阻害する BRD4 acts as a transcriptional repressor of RhoB to inhibit terminal erythropoiesis

Yijin Chen,Dawei Huo,Ye Meng,Jie Zhang,Mengmeng Huang,Qian Luo,Yulin Xu,Haiqiong Zheng,Yingli Han,Xiangjun Zeng,Yanjuan Liu,Yunfei Liu,Rui Wen,Delin Kong,Ruxiu Tie,Shanshan Pei,Nan Liu,Pengxu Qian,He Huang & Meng Zhang
Journal of Hematology & Oncology  Published:01 July 2025
DOI:https://doi.org/10.1186/s13045-025-01721-2

幹細胞による人工血液の研究:RhoBの転写抑制因子としてBRD4が末端赤血球生成を阻害する新たな役割とメカニズムを解明。(Stem cell-derived red blood cell production advances for artificial blood supply)

Abstract

Background

Terminal erythropoiesis is a complex multistep process involving coordination of gene transcription and dramatic nuclear condensation, which leads to the expulsion of nuclei to generate reticulocytes. However, we lack a comprehensive understanding of the key transcriptional and epigenetic regulators involved.

Methods

We used a high-throughput small molecule screen in primary CD34+-derived human erythroblasts to identify targets that promoted terminal erythropoiesis, and further confirmed the phenotype in different differentiation systems by inhibitors and shRNAs of different BRD4 isoforms. Then we performed RNA-seq, ATAC-seq, ChIP-qPCR, Co-IP, and reanalyzed previously-published transcriptional data and mass spectrometric data to clarify how BRD4 regulates terminal erythropoiesis.

Results

We identified that inhibitors of the bromodomain protein BRD4, an epigenetic reader and transcriptional activator together with CDK9, promoted terminal erythropoiesis from hematopoietic stem/progenitor cells and embryonic stem cells, and enhanced enucleation. Combined analysis of our RNA-seq, ATAC-seq, and previously-published transcriptional data of erythroblast differentiation at different stages confirmed that BRD4 inhibition accelerates erythroblast maturation. Unexpectedly, this BRD4 function was independent of its classical CDK9 interaction and transcriptional activation. Instead, RNA-seq, ATAC-seq, and Cut&Tag upon BRD4 inhibition revealed that BRD4 regulates erythropoiesis by inhibiting the small G protein RhoB and disrupts actin reorganization. ChIP-qPCR, Co-IP, and functional studies revealed that BRD4 acts as a transcriptional repressor by interacting with the histone methyltransferase EHMT1/2.

Conclusions

We demonstrate a non-classical role for BRD4 as a transcriptional repressor of RhoB to regulate erythroid maturation, and classical CDK9 dependent role to regulate cell proliferation of erythroblasts. Besides, we clarify RhoB’s activity and function during terminal erythropoiesis. BRD4 inhibition might be a simple method to promote in vitro blood cell production, and a candidate therapeutic target for diseases leading to dyserythropoiesis such as myelodysplastic syndromes.

細胞遺伝子工学
ad
ad
Follow
ad
タイトルとURLをコピーしました